Treatment Outcome of Palliative Chemotherapy in Inoperable Cholangiocarcinoma in Thailand

  • Published : 2013.06.30


Background: Cholangiocarcinoma is the most common cancer in males in Thailand. The outcome is poor although systemic chemotherapy has been used in attempts to improve disease control, quality of life and prolong survival in patient with unresectable and advanced disease. Materials and Methods: In this retrospective study the medical records of all patients diagnosed as having unresectable and metastatic cholangiocarcinoma and receiving systemic chemotherapy at Udonthani Cancer Hospital during January 2007 to December 2010 were reviewed. Results: Among the total of 105 patients, 21 received gemcitabine-based chemotherapy and 84 5FU-based chemotherapy. Most received platinum doublet regimens. 5FU-based regimens yielded an overall response rate (tumor control) of 23.8% and a median survival of 7.2 months while gemcitabine-based regimens yielded an overall response rate (tumor control) 19.1% and a median survival of 10.0 months. Conclusions: Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ.


  1. Anderson CD, Wright PC, Berlin J, et al (2004). Diagnosis and treatment of cholangiocarcinoma. Oncologist, 9, 43-57.
  2. Chaiwerawattana A, Sukarayodhin S, Karalak A, et al (2011). Screening, diagnosis and treatment of liver cancer and bile duct cancer. 2nd ed. National cancer Institute, Thailand
  3. Chaiyut C, Thongprasert S, Busyamas C, et al (2007). Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol, 13, 2852-4.
  4. de Groen PC, Gores GJ, LaRusso NF, et al (1999). Biliary tract cancers. N Engl J Med, 341, 1368-78.
  5. Glimelius B, Hoffman K, Sjoden P-O, et al (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 7, 593-600.
  6. Hezel AF, Zhu AX (2008). Systemic therapy for biliary tract cancers. Oncologist, 13, 415-23.
  7. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  8. Jongha P, Myung-Hwan K, Kyu-pyo Kim, et al (2009). Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver, 3, 298-305.
  9. Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51, 1-9.
  10. Khuhaprema T, Srivatanakul P, Attasara P, et al (2010). Cancer incidence in Thailand, liver and bile duct. Cancer in Thailand, 5, 31-4
  11. Khuntikao N (2005). Current concept in management of cholangiocarcinoma. Srinagarind Med J, 20, 143-9.
  12. Murad A, Mark JW, Michele M (2009). Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol, 15, 4240-62.
  13. Sararat C (2010). Hospital based cancer registry 2009. Cancer registry unit, Udonthani cancer center, Thailand
  14. Siegel R, Naishadham D, Jemal A(2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  15. Thongprasert S (2005). The role of chemotherapy in cholangiocarcinoma. Ann Oncol, 16, 93-6.
  16. Thongprasert S, Napapan S, Charoentum C, et al (2005). Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol, 16, 279-81.
  17. Valle J, Wasan H, John E, et al (2009). Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer, 101, 621-7.
  18. Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81.
  19. Yonemoto N, Furuse J, Okusaka T, et al (2007). A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol, 37, 843-51.

Cited by

  1. Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells vol.15, pp.12, 2014,
  2. Analysis of Different Ways of Drainage for Obstructive Jaundice Caused by Hilar Cholangiocarcinoma vol.15, pp.14, 2014,
  3. Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors vol.15, pp.17, 2014,
  4. In vitro and In vivo Antitumor Activity of Tiliacorinine in Human Cholangiocarcinoma vol.15, pp.17, 2014,
  5. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents vol.37, pp.8, 2016,
  6. Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice vol.49, pp.1, 2016,
  7. A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study vol.17, pp.1, 2017,